Hydroxychloroquine reduces interleukin-6 levels after myocardial infarction: The randomized, double-blind, placebo-controlled OXI pilot trial.

International Journal of Cardiology
Lotta UlanderJuha Sinisalo

Abstract

To determine the anti-inflammatory effect and safety of hydroxychloroquine after acute myocardial infarction. In this multicenter, double-blind, placebo-controlled OXI trial, 125 myocardial infarction patients were randomized at a median of 43 h after hospitalization to receive hydroxychloroquine 300 mg (n = 64) or placebo (n = 61) once daily for 6 months and, followed for an average of 32 months. Laboratory values were measured at baseline, 1, 6, and 12 months. The levels of interleukin-6 (IL-6) were comparable at baseline between study groups (p = 0.18). At six months, the IL-6 levels were lower in the hydroxychloroquine group (p = 0.042, between groups), and in the on-treatment analysis, the difference at this time point was even more pronounced (p = 0.019, respectively). The high-sensitivity C-reactive protein levels did not differ significantly between study groups at any time points. Eleven patients in the hydroxychloroquine group and four in the placebo group had adverse events leading to interruption or withdrawal of study medication, none of which was serious (p = 0.10, between groups). In patients with myocardial infarction, hydroxychloroquine reduced IL-6 levels significantly more than did placebo without causing any...Continue Reading

References

Jul 24, 2001·JAMA : the Journal of the American Medical Association·A D PradhanP M Ridker
Mar 15, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Alenka KuznikRoman Jerala
Mar 17, 2012·Lancet·UNKNOWN Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) ConsortiumJuan Pablo Casas
Jan 6, 2016·Journal of the American Heart Association·Tarun S SharmaAndroniki Bili
Aug 29, 2017·The New England Journal of Medicine·Paul M RidkerUNKNOWN CANTOS Trial Group
Jun 3, 2018·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Clotilde ChatreYves-Marie Pers
Aug 31, 2018·European Heart Journal·Kristian ThygesenUNKNOWN ESC Scientific Document Group
Nov 13, 2018·The New England Journal of Medicine·Paul M RidkerUNKNOWN CIRT Investigators
Nov 17, 2019·The New England Journal of Medicine·Jean-Claude TardifFrançois Roubille
Apr 17, 2021·Journal of the American College of Cardiology·Kaspar BrochLars Gullestad

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Related Papers

Archives of Ophthalmology
M Frenkel
The British Journal of Ophthalmology
A G Lee
Retinal Cases & Brief Reports
Michael F Marmor
MedRxiv : the Preprint Server for Health Sciences
Jose ChackoR. Premkumar
© 2021 Meta ULC. All rights reserved